-
Mc-Val-Cit-PABC-PNP: Evidence and Scope
2026-10-14
APExBIO describes Mc-Val-Cit-PABC-PNP as a cathepsin B-cleavable ADC peptide linker intended to support lysosomal payload release in targeted drug-delivery research. With no identity-matched research paper available, the defensible interpretation is limited to the supplier-reported identity, physicochemical properties, proposed mechanism, and associated evidentiary boundaries.
-
What the MERS-CoV Screen Actually Shows
2026-10-14
A 2014 cell-culture screening study identified four approved drugs that inhibited MERS-CoV replication in vitro, but it did not evaluate L-Alanyl-L-glutamine, intestinal barrier effects, animal protection, or clinical treatment.
-
Metoprolol Research: Evidence and Boundaries
2026-10-13
Metoprolol is described by APExBIO as a selective beta1-adrenergic receptor antagonist for research into cardiovascular physiology. The supplied 2025 study concerns Corydalis saxicola alkaloids in mouse models of metabolic liver disease, not metoprolol. Its pharmacokinetic findings therefore provide relevant methodological context but do not establish metoprolol efficacy, safety, tissue distribution, or clinical utility in MASLD or MASH.
-
MMAE and Tumor Plasticity: Evidence Boundaries
2026-10-13
Monomethyl auristatin E (MMAE) is described as an antimitotic antibody-drug conjugate payload, whereas the supplied nasopharyngeal carcinoma study examines HDAC inhibition as an epigenetic strategy for reversing EBV-associated dedifferentiation. The evidence supports a conceptual distinction—not a demonstrated role for MMAE in restoring differentiation, targeting EBV biology, or treating tumor plasticity.
-
Prochlorperazine-Associated Neuroleptic Malignant Syndrome
2026-10-12
This single-patient case report describes a 76-year-old man who developed a clinical syndrome consistent with neuroleptic malignant syndrome after two weeks of prochlorperazine exposure. The report emphasizes that severe fever, rigidity, altered consciousness and autonomic instability may occur without marked creatine phosphokinase elevation. Improvement followed inpatient management, but the case cannot establish incidence, comparative treatment effectiveness or definitive causality.
-
What the PDK4 Inhibitor Study Shows
2026-10-12
Lee and colleagues reported compound 8c as a potent allosteric PDK4 inhibitor with activity across biochemical, cellular, and selected mouse models. The findings support 8c as a preclinical lead, but they do not establish clinical efficacy, safety, or relevance to the separately listed Dextromethorphan hydrobromide product.
-
NETs in CML: What the TKI Study Shows
2026-10-11
A source-grounded overview of Telerman et al. (2022), examining increased neutrophil extracellular trap formation in chronic myeloid leukemia and differential effects of tyrosine kinase inhibitors, with particular attention to ponatinib and the study’s limits.
-
TUNEL Beyond Apoptosis: Reading Cell Death Signals
2026-10-10
A translational perspective on how TUNEL fluorescence can support apoptosis research while avoiding the common mistake of treating DNA fragmentation as a standalone proof of cell-death identity.
-
Angiotensin I/II (1-5): Product Overview
2026-10-10
A source-limited overview of APExBIO’s Angiotensin I/II (1-5), covering its documented peptide identity, conceptual research scope, and evidence limitations.
-
Lapatinib Beyond HER2: A Translational View
2026-10-09
Lapatinib, also known as GW572016, is best understood not only as a selective EGFR and HER2 kinase inhibitor, but as a tool for testing how receptor context shapes cancer phenotypes. A 2026 study in triple-negative breast cancer broadens the research question while also underscoring the need to distinguish phenotype-level activity from confirmed target engagement.
-
Biotin-16-UTP: Product Overview and Evidence Limits
2026-10-09
Biotin-16-UTP is a biotin-labeled uridine triphosphate analog supplied by APExBIO for conceptual use in RNA labeling research. No matched paper evidence is available for independently assessing its performance or application-specific outcomes.
-
MHY1485 as a Mechanistic Probe of mTORC1
2026-10-08
MHY1485 is an mTOR activator whose effects on autophagy require careful interpretation of pathway activity versus lysosomal clearance. This article connects the compound’s reported properties with the LMP2A–mTORC1–GCNT3 axis in nasopharyngeal carcinoma and defines the evidence boundaries for translational research.
-
Annexin V-PE Apoptosis Assay: Five Key Questions
2026-10-08
A source-grounded overview of how Annexin V-PE detects phosphatidylserine exposure, what the 2026 ALK-positive anaplastic large cell lymphoma study reported, and where the assay’s evidence and applicability remain limited.
-
ATG4B, Energy Deficiency, and AML DNA Repair
2026-10-07
A source-grounded overview of a 2025 Advanced Science study linking energy deficiency, ATG4B nuclear translocation, PRMT1–MRE11 DNA-repair signaling, and acute myeloid leukemia progression. The article reports mechanistic evidence in cellular and mouse AML models, including patient-derived xenografts, while important limitations remain around clinical applicability, independent replication, effect-size reporting, and the relationship to Repaglinide, which is listed separately by APExBIO without an established connection to the study.
-
Sulfo-NHS-LC-Biotin Product Overview
2026-10-07
Sulfo-NHS-LC-Biotin (SKU A8003) is described by APExBIO as a water-soluble reagent for covalent biotin labeling of accessible primary amines. No matched paper evidence was provided, so performance and application claims remain supplier-described rather than independently validated.